Table of Content

Chapter 1: INTRODUCTION

1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments

1.3.1. List of key players profiled in the report

1.4. Research Methodology

1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

Chapter 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO Perspective

Chapter 3: MARKET OVERVIEW

3.1. Market Definition and Scope
3.2. Key Findings

3.2.1. Top investment pockets.
3.2.2. Top winning strategies

3.3. Porter’s five force analysis
3.4. Regulatory Framework

3.4.1. FDA
3.4.2. CE Mark
3.4.3. Therapeutic Goods Administration (TGA)
3.4.4. Ministry of Health, Labour and Welfare (MHLW)

3.5. Market Share Analysis, 2019
3.6. Market Dynamics

3.6.1. Drivers

3.6.1.1. Rise in prevalence of human papilloma virus (HPV) cancer
3.6.1.2. Increase in administration of prophylactic cancer vaccines
3.6.1.3. Rise in development of new cancer vaccines
3.6.1.4. Launch and approval of new cancer vaccines in the market

3.6.2. Restraints

3.6.2.1. High cost and longer timelines required for development of cancer vaccines

3.6.3. Opportunities

3.6.3.1. High growth prospects in emerging markets

3.6.4. Impact analysis

Chapter 4: CANCER VACCINES MARKET, BY TECHNOLOGY

4.1. Overview

4.1.1. Market size and forecast

4.2. Dendritic Cells (DC) Cancer Vaccines

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country

4.3. Recombinant Cancer Vaccines

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country

4.4. Antigen/Adjuvent Cancer Vaccines

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country

4.5. Viral Vector and DNA Cancer Vaccines

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country

Chapter 5: CANCER VACCINES MARKET, BY TYPES

5.1. Overview
5.2. Market size and forecast
5.3. Preventive Cancer Vaccines

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Therapeutic Cancer Vaccines

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

Chapter 6: CANCER VACCINES MARKET, BY INDICATION

6.1. Overview
6.2. Market size and forecast
6.3. Cervical Cancer

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Prostate Cancer

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

6.5. Other Indications

6.5.1. Market size and forecast, by region
6.5.2. Market analysis, by country

Chapter 7: CANCER VACCINES MARKET, BY END USER

7.1. Overview
7.2. Market size and forecast
7.3. Pediatrics

7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country

7.4. Adults

7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country

Chapter 8: CANCER VACCINES MARKET, BY REGION

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. North America

8.2.1. Key market trends, growth factors, and opportunities
8.2.2. North America cancer vaccines market, by country

8.2.2.1. U.S.

8.2.2.1.1. U.S. cancer vaccines market, by technology
8.2.2.1.2. U.S. cancer vaccines market, by type
8.2.2.1.3. U.S. cancer vaccines market, by Indication
8.2.2.1.4. U.S. cancer vaccines market, by end user

8.2.2.3. Canada

8.2.2.3.1. Canada cancer vaccines market, by technology
8.2.2.3.2. Canada cancer vaccines market, by type
8.2.2.3.3. Canada cancer vaccines market, by indication
8.2.2.3.4. Canada cancer vaccines market, by end user

8.2.2.5. Mexico

8.2.2.5.1. Mexico cancer vaccines market, by technology
8.2.2.5.2. Mexico cancer vaccines market, by type
8.2.2.5.3. Mexico cancer vaccines market, by indication
8.2.2.5.4. Mexico cancer vaccines market, by end user

8.2.3. North America cancer vaccines market, by technology
8.2.4. North America cancer vaccines market, by type
8.2.5. North America cancer vaccines market, by indication
8.2.6. North America cancer vaccines market, by end user

8.3. Europe

8.3.1. Key market trends, growth factors, and opportunities
8.3.2. Europe cancer vaccines market, by country

8.3.2.1. Germany

8.3.2.1.1. Germany cancer vaccines market, by technology
8.3.2.1.2. Germany cancer vaccines market, by type
8.3.2.1.3. Germany cancer vaccines market, by indication
8.3.2.1.4. Germany cancer vaccines market, by end user

8.3.2.2. France

8.3.2.2.1. France cancer vaccines market, by technology
8.3.2.2.2. France cancer vaccines market, by type
8.3.2.2.3. France cancer vaccines market, by indication
8.3.2.2.4. France cancer vaccines market, by end user

8.3.2.3. UK

8.3.2.3.1. UK cancer vaccines market, by technology
8.3.2.3.2. UK cancer vaccines market, by type
8.3.2.3.3. UK cancer vaccines market, by indication
8.3.2.3.4. UK cancer vaccines market, by end user

8.3.2.4. Italy

8.3.2.4.1. Italy cancer vaccines market, by technology
8.3.2.4.2. Italy cancer vaccines market, by type
8.3.2.4.3. Italy cancer vaccines market, by indication
8.3.2.4.4. Italy cancer vaccines market, by end user

8.3.2.5. Spain

The Spain cancer vaccines market was valued at $107.67 million in 2019, and is projected to reach $158.00 million by 2027, registering a CAGR of 9.5%.

8.3.2.5.1. Spain cancer vaccines market, by technology
8.3.2.5.2. Spain cancer vaccines market, by type
8.3.2.5.3. Spain cancer vaccines market, by indication
8.3.2.5.4. Spain cancer vaccines market, by end user

8.3.2.6. Rest of Europe

8.3.2.6.1. Rest of Europe cancer vaccines market, by technology
8.3.2.6.2. Rest of Europe cancer vaccines market, by type
8.3.2.6.3. Rest of Europe cancer vaccines market, by indication
8.3.2.6.4. Rest of Europe cancer vaccines market, by end user

8.3.3. Europe cancer vaccines market, by technology
8.3.4. Europe cancer vaccines market, by type
8.3.5. Europe cancer vaccines market, by indication
8.3.6. Europe cancer vaccines market, by end user

8.4. Asia-Pacific

8.4.1. Key market trends and opportunities
8.4.2. Asia-Pacific cancer vaccines market, by country

8.4.2.1. Japan

8.4.2.1.1. Japan cancer vaccines market, by technology
8.4.2.1.2. Japan cancer vaccines market, by type
8.4.2.1.3. Japan cancer vaccines market, by indication
8.4.2.1.4. Japan cancer vaccines market, by end user

8.4.2.2. China

8.4.2.2.1. China cancer vaccines market, by technology
8.4.2.2.2. China cancer vaccines market, by type
8.4.2.2.3. China cancer vaccines market, by indication
8.4.2.2.4. China cancer vaccines market, by end user

8.4.2.3. Australia

8.4.2.3.1. Australia cancer vaccines market, by technology
8.4.2.3.2. Australia cancer vaccines market, by type
8.4.2.3.3. Australia cancer vaccines market, by indication
8.4.2.3.4. Australia cancer vaccines market, by end user

8.4.2.4. India

8.4.2.4.1. India cancer vaccines market, by technology
8.4.2.4.2. India cancer vaccines market, by type
8.4.2.4.3. India cancer vaccines market, by indication
8.4.2.4.4. India cancer vaccines market, by end user

8.4.2.5. South Korea

8.4.2.5.1. South Korea cancer vaccines market, by technology
8.4.2.5.2. South Korea cancer vaccines market, by type
8.4.2.5.3. South Korea cancer vaccines market, by indication
8.4.2.5.4. South Korea cancer vaccines market, by end user

8.4.2.6. Rest of Asia-Pacific

8.4.2.6.1. Rest of Asia-Pacific cancer vaccines market, by technology
8.4.2.6.2. Rest of Asia-Pacific cancer vaccines market, by type
8.4.2.6.3. Rest of Asia-Pacific cancer vaccines market, by indication
8.4.2.6.4. Rest of Asia-Pacific cancer vaccines market, by end user

8.4.3. Asia-Pacific cancer vaccines market, by technology
8.4.4. Asia-Pacific cancer vaccines market, by type
8.4.5. Asia-Pacific cancer vaccines market, by indication
8.4.6. Asia-Pacific cancer vaccines market, by end user

8.5. LAMEA

8.5.1. Key market trends, growth factors, and opportunities
8.5.2. LAMEA cancer vaccines market, by country

8.5.2.1. Brazil

8.5.2.1.1. Brazil cancer vaccines market, by technology
8.5.2.1.2. Brazil cancer vaccines market, by type
8.5.2.1.3. Brazil cancer vaccines market, by indication
8.5.2.1.4. Brazil cancer vaccines market, by end user

8.5.2.2. Argentina

8.5.2.2.1. Argentina cancer vaccines market, by technology
8.5.2.2.2. Argentina cancer vaccines market, by type
8.5.2.2.3. Argentina cancer vaccines market, by indication
8.5.2.2.4. Argentina cancer vaccines market, by end user

8.5.2.3. Turkey

8.5.2.3.1. Turkey cancer vaccines market, by technology
8.5.2.3.2. Turkey cancer vaccines market, by type
8.5.2.3.3. Turkey cancer vaccines market, by indication
8.5.2.3.4. Turkey cancer vaccines market, by end user

8.5.2.4. South Africa

8.5.2.4.1. South Africa cancer vaccines market, by technology
8.5.2.4.2. South Africa cancer vaccines market, by type
8.5.2.4.3. South Africa cancer vaccines market, by indication
8.5.2.4.4. South Africa cancer vaccines market, by end user

8.5.2.5. Rest of LAMEA

8.5.2.5.1. Rest of LAMEA cancer vaccines market, by technology
8.5.2.5.2. Rest of LAMEA cancer vaccines market, by type
8.5.2.5.3. Rest of LAMEA cancer vaccines market, by indication
8.5.2.5.4. Rest of LAMEA cancer vaccines market, by end user

8.5.3. LAMEA cancer vaccines market, by technology
8.5.4. LAMEA cancer vaccines market, by type
8.5.5. LAMEA cancer vaccines market, by indication
8.5.6. LAMEA cancer vaccines market, by end user

Chapter 9: COMPANY PROFILES

9.1. Advaxis Inc.

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments

9.2. Amgen Inc.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance

9.3. Dynavax Technologies Corporation

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance

9.4. Generex Biotechnology Corporation

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance

9.5. GlaxoSmithKline plc (GSK)

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments

9.6. Immunocellular Therapeutics, Ltd

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio

9.7. Merck & Co., Inc.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments

9.8. SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION)

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Key strategic moves and developments

9.9. UbiVac

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Key strategic moves and developments

9.10. Vaccinogen, Inc.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio



List of Figures



FIGURE 01. GLOBAL CANCER VACCINES MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2017-2019
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2019
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2017-2019
FIGURE 06. MODERATE POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. HIGH THREAT OF SUBSTITUTION
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. HIGH COMPETITIVE RIVALRY
FIGURE 11. MARKET SHARE ANALYSIS, 2019
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DENDRITIC CELLS (DC) CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIGEN/ADJUVENT CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR AND DNA CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PROSTATE CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PADIATRICS CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF ADULTS CANCER VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 24. ADVAXIS NET SALES, 2017–2019 ($MILLION)
FIGURE 25. AMGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 26. AMGEN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 27. DYNAVAX TECHNOLOGIES: NET SALES, 2017–2019 ($MILLION)
FIGURE 28. GENEREX BIOTECHNOLOGY: NET SALES, 2018–2019 ($MILLION)
FIGURE 29. GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 30. GSK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31. GSK: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32. MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 33. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 34. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2019 (%)


List of Tables



TABLE 01. GLOBAL CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 02. DENDRITIC CELLS (DC) CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 03. RECOMBINANT CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 04. ANTIGEN/ADJUVENT CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 05. VIRAL VECTOR AND DNA CANCER VACCINES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 06. GLOBAL CANCER VACCINES MARKET, BY TYPES, 2019-2027 ($MILLION)
TABLE 07. PREVENTIVE CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 08. THERAPEUTIC CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 09. GLOBAL CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 10. CERVICAL CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 11. PROSTATE CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 12. OTHERS INDICATIONS CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 13. GLOBAL CANCER VACCINES MARKET REVENUE, BY END USER, 2019-2027 ($MILLION)
TABLE 14. PEDIATRICS CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 15. ADULTS CANCER VACCINES MARKET, BY REGION 2019-2027($MILLION)
TABLE 16. CANCER VACCINES MARKET REVENUE, BY REGION, 2019-2027 ($MILLION)
TABLE 17. NORTH AMERICA CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 18. U.S. CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 19. U.S. CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 20. U.S. CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 21. U.S. CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 22. CANADA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 23. CANADA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 24. CANADA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 25. CANADA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 26. MEXICO CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 27. MEXICO CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 28. MEXICO CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 29. MEXICO CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 30. NORTH AMERICA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 31. NORTH AMERICA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 32. NORTH AMERICA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 33. NORTH AMERICA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 34. EUROPE CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 35. GERMANY CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 36. GERMANY CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 37. GERMANY CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 38. GERMANY CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 39. FRANCE CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 40. FRANCE CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 41. FRANCE CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 42. FRANCE CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 43. UK CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 44. UK CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 45. UK CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 46. UK CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 47. ITALY CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 48. ITALY CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 49. ITALY CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 50. ITALY CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 51. SPAIN CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 52. SPAIN CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 53. SPAIN CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 54. SPAIN CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 55. REST OF EUROPE CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 56. REST OF EUROPE CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 57. REST OF EUROPE CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 58. REST OF EUROPE CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 59. EUROPE CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 60. EUROPE CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 61. EUROPE CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 62. EUROPE CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 63. ASIA-PACIFIC CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 64. JAPAN CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 65. JAPAN CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 66. JAPAN CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 67. JAPAN CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 68. CHINA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 69. CHINA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 70. CHINA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 71. CHINA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 72. AUSTRALIA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 73. AUSTRALIA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 74. AUSTRALIA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 75. AUSTRALIA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 76. INDIA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 77. INDIA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 78. INDIA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 79. INDIA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 80. SOUTH KOREA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 81. SOUTH KOREA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 82. SOUTH KOREA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 83. SOUTH KOREA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 88. ASIA-PACIFIC CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 89. ASIA-PACIFIC CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 90. ASIA-PACIFIC CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 91. ASIA-PACIFIC CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 92. LAMEA CANCER VACCINES MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 93. BRAZIL CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 94. BRAZIL CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 95. BRAZIL CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 96. BRAZIL CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 97. ARGENTINA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 98. ARGENTINA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 99. ARGENTINA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 100. ARGENTINA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 101. TURKEY CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 102. TURKEY CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 103. TURKEY CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 104. TURKEY CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 105. SOUTH AFRICA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 106. SOUTH AFRICA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 107. SOUTH AFRICA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 108. SOUTH AFRICA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 109. REST OF LAMEA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 110. REST OF LAMEA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 111. REST OF LAMEA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 112. REST OF LAMEA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 113. LAMEA CANCER VACCINES MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 114. LAMEA CANCER VACCINES MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 115. LAMEA CANCER VACCINES MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 116. LAMEA CANCER VACCINES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 117. ADVAXIS: COMPANY SNAPSHOT
TABLE 118. ADVAXIS: PRODUCT PORTFOLIO
TABLE 119. ADVAXIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 120. AMGEN: COMPANY SNAPSHOT
TABLE 121. AMGEN: PRODUCT PORTFOLIO
TABLE 122. DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 123. DYNAVAX TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 124. GENEREX BIOTECHNOLOGY: COMPANY SNAPSHOT
TABLE 125. GENEREX BIOTECHNOLOGY: PRODUCT PORTFOLIO
TABLE 126. GSK: COMPANY SNAPSHOT
TABLE 127. GLAXOSMITHKLINE PLC.: OERATING SEGMENT
TABLE 128. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 129. GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 130. IMMUNOCELLULAR: COMPANY SNAPSHOT
TABLE 131. IMMUNOCELLULAR: PRODUCT PORTFOLIO
TABLE 132. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 133. MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 134. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 135. MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 136. SANPOWER GROUP: COMPANY SNAPSHOT
TABLE 137. SANPOWER GROUP: OERATING SEGMENT
TABLE 138. SANPOWER GROUP: PRODUCT PORTFOLIO
TABLE 139. SANPOWER GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 140. UBIVAC: COMPANY SNAPSHOT
TABLE 141. UBIVAC.: PRODUCT PORTFOLIO
TABLE 142. UBIVAC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 143. VACCINOGEN: COMPANY SNAPSHOT
TABLE 144. VACCINOGEN: PRODUCT PORTFOLIO